Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery

  • Pluristem Therapeutics Inc PSTI announced topline results from its Phase 3 study of intramuscular administration of allogeneic PLX-PAD cells for muscle injury following arthroplasty for hip fracture. 
  • The 240-subject study did not meet the primary endpoint, the Short Physical Performance Battery (SPPB) test at week 26. The SPPB is a series of physical performance tests used in older persons to assess lower extremity function and mobility.
  • PLX-PAD was demonstrated to be an effective accelerator of muscle strength and regeneration. 
  • Related: Pluristem's PLX-R18 Shows Meaningful Advantage Over Other Treatments In Transplant Patients.
  • A significant increase in Hip Abduction Strength (HAS) was observed at week 26 and week 52.
  • In the injured leg, PLX-PAD cells showed an increase of 3.2kg from week 6 to week 26 compared to 1.3kg in the placebo group. At 52 weeks, the difference was 4kgs.
  • In the uninjured leg, PLX-PAD cells showed an increase of 2.3kg vs. 0.51kg in the placebo group, a 1.8kg difference, with a 4kg difference at 52 weeks.
  • A positive trend in a 6-minute walk test at week 52 was observed, showing an increase in walking distance.
  • Price Action: PSTI shares are down 7.55% at $1.10 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!